

Human GITR (TNFRSF18) Protein (C-Fc-Avi)

| | |
|---------------------------|-----------------------------|
| Catalog Number: | 811601, 811602 |
| Size: | 25 ug, 100 ug |
| Target Name: | TNFRSF18, AITR, GITR, CD357 |
| Regulatory Status: | RUO |

PRODUCT DETAILS

| | |
|-------------------------------|--|
| Application: | ELISA, BLI |
| Format: | Liquid, Purified |
| Expression Host: | CHO |
| Species: | Human |
| Sources: | Recombinant Human GITR/TNFRSF18 (Gln26-Glu161) with C-terminus Fc-Avi-tag is expressed in CHO cell. |
| Accession Number: | Q9Y5U5 |
| Molecular Weight: | The protein has a predicted molecular weight of 42.9 kDa. Under DTT-reducing conditions, it migrates at approximately 45-50 kDa on SDS-PAGE. |
| Affinity Tag: | C-Fc-Avi |
| Purity: | >95% based on SDS-PAGE under reducing condition |
| Formulation: | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level: | Not tested |
| Protein Concentration: | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling: | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |

BACKGROUND INFORMATION

Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), also known as CD357 or TNFRSF18, is a co-stimulatory receptor that plays an important role in regulating T cell activation, survival, and immune balance. GITR is constitutively expressed at high levels on regulatory T cells (Tregs) and at lower levels on naïve conventional T cells, with expression rapidly upregulated following T cell activation. It is also expressed on natural killer (NK) cells and some myeloid populations. Through its signaling, GITR influences both effector and regulatory arms of the immune system.

Structurally, GITR is a type I transmembrane glycoprotein and a member of the tumor necrosis factor receptor (TNFR) superfamily.


Its extracellular region contains cysteine-rich domains typical of TNFR family members that mediate ligand binding. GITR has a single transmembrane segment and a cytoplasmic tail that lacks intrinsic enzymatic activity but recruits TNF receptor-associated factors (TRAFs), particularly TRAF2 and TRAF5. These adaptor proteins initiate downstream signaling cascades, including activation of NF- κ B and MAPK pathways, which promote cell survival, proliferation, and cytokine production.

The primary ligand for GITR is GITR ligand (GITRL), also known as TNFSF18, which is expressed on activated antigen-presenting cells such as dendritic cells, macrophages, and B cells, as well as on endothelial cells in inflamed tissues. Engagement of GITR by GITRL provides a co-stimulatory signal that enhances effector T cell activation and resistance to suppression. In regulatory T cells, GITR signaling can transiently reduce suppressive function, thereby shifting the immune balance toward activation in certain contexts.

GITR has been implicated in a variety of disease settings. In autoimmune and inflammatory diseases, heightened GITR signaling may contribute to excessive T cell activation and tissue damage by weakening regulatory control. In allergic disease, GITR can promote Th2 responses and inflammation. In cancer, GITR is highly expressed on tumor-infiltrating Tregs, where it contributes to immune suppression within the tumor microenvironment. At the same time, GITR expression on effector T cells provides an opportunity to enhance anti-tumor immunity.


Therapeutically, GITR is an active target in immuno-oncology. Agonistic antibodies targeting GITR aim to simultaneously stimulate effector T cells and attenuate Treg-mediated suppression within tumors, thereby enhancing anti-tumor immune responses. These agents are being evaluated alone and in combination with immune checkpoint inhibitors. Conversely, strategies to inhibit GITR-GITRL interactions are being explored for the treatment of autoimmune and inflammatory diseases, highlighting GITR's dual relevance as both a driver of immunity and a contributor to immune-mediated pathology.

PRODUCT DATA



Human GITR (TNFRSF18) (C-Fc-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.



Human GITRL (TNFRSF18) (N-His) is coated at 2 ug/mL (200 ng/well). Human GITR-Fc-Avi can bind Human GITRL protein in dose-dependent manner with the ED50 of 10-50 ng/mL